發送短信 : Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

__    __   _    _     ______    _____     _  _   
\ \\ / // | || | ||  /_   _//  |  ___||  | \| || 
 \ \/ //  | || | ||  `-| |,-   | ||__    |  ' || 
  \  //   | \\_/ ||    | ||    | ||__    | .  || 
   \//     \____//     |_||    |_____||  |_|\_|| 
    `       `---`      `-`'    `-----`   `-` -`